UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000051799 |
|---|---|
| Receipt number | R000059113 |
| Scientific Title | Efficacy of trazodone for delirium in cancer patients: a systematic review |
| Date of disclosure of the study information | 2023/08/02 |
| Last modified on | 2023/08/31 15:53:26 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Efficacy of trazodone for delirium in cancer patients: a systematic review
Acronym
Efficacy of trazodone for delirium in cancer patients: a systematic review
Scientific Title
Efficacy of trazodone for delirium in cancer patients: a systematic review
Scientific Title:Acronym
Efficacy of trazodone for delirium in cancer patients: a systematic review
Region
| Japan |
Condition
Condition
Cancer
Classification by specialty
| Hematology and clinical oncology | Psychiatry |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To verify the efficacy of trazodone for delirium in cancer patients.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Severity of delirium
Key secondary outcomes
Duration of delirium, somnolence, tumbling and falls.
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1.patients with cancer (more than or equal to 80%)
2.patients with delirium
3.Trials including the administration of trazodone
The study design to be considered for inclusion is as follows:
1.If there were at least two randomized controlled trial (RCT)s, inclusion was completed.
2.If there were less than 2 RCTs, we included non-RCTs or observational studies with control groups.
3.If there were no RCTs/non-RCTs/observational studies with control groups, single-arm observational studies were considered for inclusion.
Key exclusion criteria
1.Duplicate publications
2.Conference proceedings
Target sample size
Research contact person
Name of lead principal investigator
| 1st name | Akiharu |
| Middle name | |
| Last name | Okamoto |
Organization
Mie University Hospital
Division name
Department of Pharmacy
Zip code
514-8507
Address
2-174 Edobashi, Tsu city, Mie, Japan
TEL
059-232-1111
okamotoa@med.mie-u.ac.jp
Public contact
Name of contact person
| 1st name | Akiharu |
| Middle name | |
| Last name | Okamoto |
Organization
Mie University Hospital
Division name
Department of Pharmacy
Zip code
514-8507
Address
2-174 Edobashi, Tsu city, Mie, Japan
TEL
059-232-1111
Homepage URL
okamotoa@med.mie-u.ac.jp
Sponsor or person
Institute
Mie University
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
N/A
Address
N/A
Tel
N/A
N/A
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2023 | Year | 08 | Month | 02 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2023 | Year | 07 | Month | 31 | Day |
Date of IRB
Anticipated trial start date
| 2023 | Year | 09 | Month | 01 | Day |
Last follow-up date
| 2024 | Year | 08 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Data sources and search strategy
We will conduct a systematic review to identify efficacy of trazodone for delirium in cancer patients. This systematic review will be conducted using the electronic databases, Medical Journal Web Edition ver. 5, Cochrane Library, and MEDLINE, with the keywords "delirium," "cancer," and "trazodone" for all literature reported up to 2023/08/31.
Selection of studies in included studies
Two review authors will independently check to ensure that studies meet the inclusion criteria. Any discrepancies in study selection will be resolved by discussion or discussion with a third author.
Management information
Registered date
| 2023 | Year | 08 | Month | 02 | Day |
Last modified on
| 2023 | Year | 08 | Month | 31 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059113
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
